Immunotherapy is the process of treating diseases with the help of a person’s own immune system to fight against diseases such as cancer. The process of cancer immunotherapy can be done in different ways such as stimulating the patient’s immune system to work harder or smarter to attack cancer cells and the patient can be given artificial immune-system protein. Immunotherapy helps in boosting the immune system to attack the cancer cells specifically. The global cancer immunotherapy market is expected to grow at a CAGR of 15.7% from 2017 to 2025.
According to type, the market is divided into monoclonal antibodies, immunomodulators, cancer vaccines, and checkpoint inhibitors. According to application, the market is divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, head and neck cancer, and others. Geographic breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and LAMEA.
Market Dynamics:
Drivers:
• Increasing funding from different government and private organizations for the research and development of cancer immunotherapy.
• Increasing incidence of cancer worldwide.
• Rising approvals for the clinical trials of cancer immunotherapy.
• Rising acceptance of cancer immunotherapy
Restraints:
• High cost of cancer immunotherapy.
Market Players:
The top players in the global cancer immunotherapy market include Amgen, AstraZeneca, Bayer AG, F. Hoffman La-Roche, Bristol-Myers Squibb, Janssen Global Services, LLC, Eli Lilly and Company, Merck & Co., Inc., Novartis, and Pfizer. Market players for cancer immunotherapy market are adopting different strategies such as product development, product approval, acquisition, and collaboration to keep pace with the evolving market trends.
KEY TAKEAWAYS
MARKET LANDSCAPE
• By Type
? Monoclonal Antibodies
? Immunomodulators
? Cancer Vaccines
? Checkpoint Inhibitors
• By Application
? Breast Cancer
? Lung Cancer
? Colorectal Cancer
? Prostate Cancer
? Melanoma
? Head and Neck Cancer
? Others
• By Geography
? North America
o U.S.
o Canada
o Mexico
? Europe
o UK
o Germany
o France
o Spain
o Italy
o Rest of Europe
? Asia-Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia-Pacific
? LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
1. Executive summary
1.1. Key findings
1.2. Market attractiveness and trend analysis
1.3. Competitive landscape and recent industry development analysis
2. Introduction
2.1. Report description
2.2. Scope and definitions
2.3. Research methodology
3. Market landscape
3.1. Growth drivers
3.1.1. Impact analysis
3.2. Restrains and challenges
3.2.1. Impact analysis
3.3. Porter’s analysis
3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Industry rivalry
3.3.5. Threat of new entrants
3.4. Global cancer immunotherapy market shares analysis, 2014-2025
3.4.1. Global cancer immunotherapy market share by type, 2014-2025
3.4.2. Global cancer immunotherapy market share by application, 2014-2025
3.4.3. Global cancer immunotherapy market share by geography, 2014-2025
4. Global cancer immunotherapy market by type
4.1. Monoclonal antibodies
4.1.1. Historical market size by region, 2014-2016
4.1.2. Market forecast by region, 2017-2025
4.2. Immunomodulators
4.2.1. Historical market size by region, 2014-2016
4.2.2. Market forecast by region, 2017-2025
4.3. Cancer vaccines
4.3.1. Historical market size by region, 2014-2016
4.3.2. Market forecast by region, 2017-2025
4.4. Checkpoint inhibitors
4.4.1. Historical market size by region, 2014-2016
4.4.2. Market forecast by region, 2017-2025
5. Global cancer immunotherapy market by application
5.1. Breast cancer
5.1.1. Historical market size by region, 2014-2016
5.1.2. Market forecast by region, 2017-2025
5.2. Lung cancer
5.2.1. Historical market size by region, 2014-2016
5.2.2. Market forecast by region, 2017-2025
5.3. Colorectal cancer
5.3.1. Historical market size by region, 2014-2016
5.3.2. Market forecast by region, 2017-2025
5.4. Prostate cancer
5.4.1. Historical market size by region, 2014-2016
5.4.2. Market forecast by region, 2017-2025
5.5. Melanoma
5.5.1. Historical market size by region, 2014-2016
5.5.2. Market forecast by region, 2017-2025
5.6. Head and neck cancer
5.6.1. Historical market size by region, 2014-2016
5.6.2. Market forecast by region, 2017-2025
5.7. Others
5.7.1. Historical market size by region, 2014-2016
5.7.2. Market forecast by region, 2017-2025
6. Global cancer immunotherapy market by geography
6.1. North America
6.1.1. U.S.
6.1.1.1. Historical market size, 2014-2016
6.1.1.2. Market forecast, 2017-2025
6.1.2. Canada
6.1.2.1. Historical market size, 2014-2016
6.1.2.2. Market forecast, 2017-2025
6.1.3. Mexico
6.1.3.1. Historical market size, 2014-2016
6.1.3.2. Market forecast, 2017-2025
6.2. Europe
6.2.1. UK
6.2.1.1. Historical market size, 2014-2016
6.2.1.2. Market forecast, 2017-2025
6.2.2. Germany
6.2.2.1. Historical market size, 2014-2016
6.2.2.2. Market forecast, 2017-2025
6.2.3. France
6.2.3.1. Historical market size, 2014-2016
6.2.3.2. Market forecast, 2017-2025
6.2.4. Spain
6.2.4.1. Historical market size, 2014-2016
6.2.4.2. Market forecast, 2017-2025
6.2.5. Italy
6.2.5.1. Historical market size, 2014-2016
6.2.5.2. Market forecast, 2017-2025
6.2.6. Rest of Europe
6.2.6.1. Historical market size, 2014-2016
6.2.6.2. Market forecast, 2017-2025
6.3. Asia-Pacific
6.3.1. China
6.3.1.1. Historical market size, 2014-2016
6.3.1.2. Market forecast, 2017-2025
6.3.2. Japan
6.3.2.1. Historical market size, 2014-2016
6.3.2.2. Market forecast, 2017-2025
6.3.3. India
6.3.3.1. Historical market size, 2014-2016
6.3.3.2. Market forecast, 2017-2025
6.3.4. Australia
6.3.4.1. Historical market size, 2014-2016
6.3.4.2. Market forecast, 2017-2025
6.3.5. South Korea
6.3.5.1. Historical market size, 2014-2016
6.3.5.2. Market forecast, 2017-2025
6.3.6. Rest of Asia-Pacific
6.3.6.1. Historical market size, 2014-2016
6.3.6.2. Market forecast, 2017-2025
6.4. LAMEA
6.4.1. Brazil
6.4.1.1. Historical market size, 2014-2016
6.4.1.2. Market forecast, 2017-2025
6.4.2. Saudi Arabia
6.4.2.1. Historical market size, 2014-2016
6.4.2.2. Market forecast, 2017-2025
6.4.3. South Africa
6.4.3.1. Historical market size, 2014-2016
6.4.3.2. Market forecast, 2017-2025
6.4.4. Rest of LAMEA
6.4.4.1. Historical market size, 2014-2016
6.4.4.2. Market forecast, 2017-2025
7. Company profiles
7.1. Amgen
7.1.1. Overview
7.1.2. Financials and business segments
7.1.3. Recent developments
7.2. Astrazeneca
7.2.1. Overview
7.2.2. Financials and business segments
7.2.3. Recent developments
7.3. Bayer ag
7.3.1. Overview
7.3.2. Financials and business segments
7.3.3. Recent developments
7.4. F. Hoffman la-roche
7.4.1. overview
7.4.2. Financials and business segments
7.4.3. Recent developments
7.5. Bristol-myers squibb
7.5.1. Overview
7.5.2. Financials and business segments
7.5.3. Recent developments
7.6. Janssen global services, llc
7.6.1. overview
7.6.2. Financials and business segments
7.6.3. Recent developments
7.7. Eli lilly and company
7.7.1. Overview
7.7.2. Financials and business segments
7.7.3. Recent developments
7.8. Merck & co., inc.
7.8.1. overview
7.8.2. Financials and business segments
7.8.3. Recent developments
7.9. Novartis
7.9.1. Overview
7.9.2. Financials and business segments
7.9.3. Recent developments
7.10. Pfizer inc.
7.10.1. Overview
7.10.2. Financials and business segments
7.10.3. Recent developments
Table 1.Cancer Immunotherapy Market Share, by Type, 2014-2025
Table 2.Cancer Immunotherapy Market Share, by Application, 2014-2025
Table 3.Cancer Immunotherapy Market Share, by Region, 2014-2025
Table 4.Cancer Immunotherapy Market Value for Monoclonal Antibodies, by Region, 2017-2025, $million
Table 5.Cancer Immunotherapy Market Value for Immunomodulators, by Region, 2017-2025, $million
Table 6.Cancer Immunotherapy Market Value for Cancer Vaccines, by Region, 2017-2025, $million
Table 7.Cancer Immunotherapy Market Value for Checkpoint Inhibitors, by Region, 2017-2025, $million
Table 8.Cancer Immunotherapy Market Value for Breast Cancer, by Region, 2017-2025, $million
Table 9.Cancer Immunotherapy Market Value for Lung Cancer, by Region, 2017-2025, $million
Table 10.Cancer Immunotherapy Market Value for Colorectal Cancer, by Region, 2017-2025, $million
Table 11.Cancer Immunotherapy Market Value for Prostate Cancer, by Region, 2017-2025, $million
Table 12.Cancer Immunotherapy Market Value for Melanoma, by Region, 2017-2025, $million
Table 13.Cancer Immunotherapy Market Value for Head and Neck Cancer, by Region, 2017-2025, $million
Table 14.Cancer Immunotherapy Market Value for Others, by Region, 2017-2025, $million
Table 15.Cancer Immunotherapy Market Value for North America, by Country, 2014-2025, $million
Table 16.Cancer Immunotherapy Market Value for North America, by Type, 2014-2025, $million
Table 17.Cancer Immunotherapy Market Value for North America, by Application, 2014-2025, $million
Table 18.Cancer Immunotherapy Market Value for Europe, by Country, 2014-2025, $million
Table 19.Cancer Immunotherapy Market Value for Europe, by Type, 2014-2025, $million
Table 20.Cancer Immunotherapy Market Value for Europe, by Application, 2014-2025, $million
Table 21.Cancer Immunotherapy Market Value for Asia-Pacific, by Country, 2014-2025, $million
Table 22.Cancer Immunotherapy Market Value for Asia-Pacific, by Type, 2014-2025, $million
Table 23.Cancer Immunotherapy Market Value for Asia-Pacific, by Application, 2014-2025, $million
Table 24.Cancer Immunotherapy Market Value for LAMEA, by Country, 2014-2025, $million
Table 25.Cancer Immunotherapy Market Value for LAMEA, by Type, 2014-2025, $million
Table 26.Cancer Immunotherapy Market Value for LAMEA, by Application, 2014-2025, $million
Table 27. Amgen - Company Snapshot
Table 28. AstraZeneca - Company Snapshot
Table 29. Bayer AG - Company Snapshot
Table 30. F. Hoffman La-Roche - Company Snapshot
Table 31. Janssen Global Services, LLC - Company Snapshot
Table 32. Eli Lilly and Company - Company Snapshot
Table 33. Merck & Co., Inc. - Company Snapshot
Table 34. Novartis - Company Snapshot
Table 35. Pfizer - Company Snapshot
Table 36. Bristol-Myers Squibb - Company Snapshot
Figure 1.Cancer Immunotherapy: Monoclonal Antibodies Market Value, 2014-2016, $million
Figure 2.Cancer Immunotherapy: Immunomodulators Market Value, 2014-2016, $million
Figure 3.Cancer Immunotherapy: Cancer Vaccines Market Value, 2014-2016, $million
Figure 4.Cancer Immunotherapy: Checkpoint Inhibitors Market Value, 2014-2016, $million
Figure 5.Cancer Immunotherapy: Breast Cancer Market Value, 2014-2016, $million
Figure 6.Cancer Immunotherapy: Lung Cancer Market Value, 2014-2016, $million
Figure 7.Cancer Immunotherapy: Colorectal Cancer Market Value, 2014-2016, $million
Figure 8.Cancer Immunotherapy: Prostate Cancer Market Value, 2014-2016, $million
Figure 9.Cancer Immunotherapy: Melanoma Market Value, 2014-2016, $million
Figure 10.Cancer Immunotherapy: Head and Neck Cancer Market Value, 2014-2016, $million
Figure 11.Cancer Immunotherapy: Others Market Value, 2014-2016, $million
Figure 12.Cancer Immunotherapy: U.S. Market Value, 2014-2016, $million
Figure 13.Cancer Immunotherapy: U.S. Market Value, 2017-2025, $million
Figure 14.Cancer Immunotherapy: Canada Market Value, 2014-2016, $million
Figure 15.Cancer Immunotherapy: Canada Market Value, 2017-2025, $million
Figure 16.Cancer Immunotherapy: Mexico Market Value, 2014-2016, $million
Figure 17.Cancer Immunotherapy: Mexico Market Value, 2017-2025, $million
Figure 18.Cancer Immunotherapy: UK Market Value, 2014-2016, $million
Figure 19.Cancer Immunotherapy: UK Market Value, 2017-2025, $million
Figure 20.Cancer Immunotherapy: Germany Market Value, 2014-2016, $million
Figure 21.Cancer Immunotherapy: Germany Market Value, 2017-2025, $million
Figure 22.Cancer Immunotherapy: France Market Value, 2014-2016, $million
Figure 23.Cancer Immunotherapy: France Market Value, 2017-2025, $million
Figure 24.Cancer Immunotherapy: Spain Market Value, 2014-2016, $million
Figure 25.Cancer Immunotherapy: Spain Market Value, 2017-2025, $million
Figure 26.Cancer Immunotherapy: Italy Market Value, 2014-2016, $million
Figure 27.Cancer Immunotherapy: Italy Market Value, 2017-2025, $million
Figure 28.Cancer Immunotherapy: Rest of Europe Market Value, 2014-2016, $million
Figure 29.Cancer Immunotherapy: Rest of Europe Market Value, 2017-2025, $million
Figure 30.Cancer Immunotherapy: China Market Value, 2014-2016, $million
Figure 31.Cancer Immunotherapy: China Market Value, 2017-2025, $million
Figure 32.Cancer Immunotherapy: Japan Market Value, 2014-2016, $million
Figure 33.Cancer Immunotherapy: Japan Market Value, 2017-2025, $million
Figure 34.Cancer Immunotherapy: India Market Value, 2014-2016, $million
Figure 35.Cancer Immunotherapy: India Market Value, 2017-2025, $million
Figure 36.Cancer Immunotherapy: Australia Market Value, 2014-2016, $million
Figure 37.Cancer Immunotherapy: Australia Market Value, 2017-2025, $million
Figure 38.Cancer Immunotherapy: South Korea Market Value, 2014-2016, $million
Figure 39.Cancer Immunotherapy: South Korea Market Value, 2017-2025, $million
Figure 40.Cancer Immunotherapy: Rest of Asia-Pacific Market Value, 2014-2016, $million
Figure 41.Cancer Immunotherapy: Rest of Asia-Pacific Market Value, 2017-2025, $million
Figure 42.Cancer Immunotherapy: Brazil Market Value, 2014-2016, $million
Figure 43.Cancer Immunotherapy: Brazil Market Value, 2017-2025, $million
Figure 44.Cancer Immunotherapy: Saudi Arabia Market Value, 2014-2016, $million
Figure 45.Cancer Immunotherapy: Saudi Arabia Market Value, 2017-2025, $million
Figure 46.Cancer Immunotherapy: South Africa Market Value, 2014-2016, $million
Figure 47.Cancer Immunotherapy: South Africa Market Value, 2017-2025, $million
Figure 48.Cancer Immunotherapy: Rest of LAMEA Market Value, 2014-2016, $million
Figure 49.Cancer Immunotherapy: Rest of LAMEA Market Value, 2017-2025, $million
